Share this Page:
The following video is an interview between PracticeUpdate and Dr Bradley Somer, Assistant Professor in the Department of Haematology/Oncology at the University of Tennessee Health Science Center at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago last week.
During the interview, Dr Somer talks about the results from a recent clinical trial of pembrolizumab, an immune checkpoint inhibitor, in combination with a drug called epacadostat, which is an oral IDO1 inhibitor that regulates the immune system, in people with advanced kidney cancer. He also touched upon other immunotherapy combinations, as well as adjuvant therapy with vascular endothelial growth factor (VEGF) inhibitors.
